SCHEMBL2865428

SCHEMBL2865428

CCOCCOCCOCCOCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.50
THRB P10828 2/20 0.43
GLA P06280 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EPHX2 P34913 2/20 0.38
PTGS1 P23219 1/20 0.37
FFAR3 O14843 1/20 0.36
CTH P32929 1/20 0.36
CBS P35520 1/20 0.36
THPO P40225 1/20 0.36
CES2 O00748 1/20 0.35
PAM P19021 2/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1056083 1.00 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL29525974 1.00 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL6275021 1.00 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL22609510 1.00 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL1172675 0.97 ALDH1A1 (0.52) ALDH1A1TSHRTHRBGLAL3MBTL1
Ethylene SCHEMBL8946643 0.95 ALDH1A1 (0.46) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL19066801 0.95 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1
SCHEMBL30523306 0.93 ALDH1A1 (0.45) ALDH1A1TSHRTHRBGLAL3MBTL1
Ethylene Glycol SCHEMBL8984224 0.93 ALDH1A1 (0.48) ALDH1A1TSHRTHRBGLAL3MBTL1
Ethylene Glycol SCHEMBL8946650 0.91 ALDH1A1 (0.50) ALDH1A1TSHRTHRBGLAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3955937-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2022-02-23 EP claimed
WO-2020212760-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2020-10-22 WO claimed
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2019-08-27 US claimed
US-9649713-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2017-05-16 US claimed
US-20170064823-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2017-03-02 US claimed
US-9532493-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2016-12-27 US claimed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
US-20250331107-A1 ORGANIC FILM AND METHOD FOR PRODUCING SAME SHIKOKU CHEM (JP) 2025-10-23 US disclosed
EP-4624466-A1 DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Innocure Therapeutics, Inc. (KR) 2025-10-01 EP disclosed
US-20250263580-A1 METAL SURFACE TREATMENT LIQUID SHIKOKU CHEMICALS CORPORATION (JP) 2025-08-21 US disclosed
EP-4580405-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL Oerth Bio LLC (US) 2025-07-09 EP disclosed
US-20250215572-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY SHIKOKU CHEMICALS CORPORATION (JP) 2025-07-03 US disclosed
EP-4506488-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY Shikoku Chemicals Corporation (JP) 2025-02-12 EP disclosed
US-20070293442-A1 ANTITHROMBOTIC COMPOUND SANOFI-AVENTIS (FR) 2007-12-20 US disclosed
US-20070246134-A1 Phenylnaphthylimidazole Compound and Usage of the Same SHIKOKU CHEMICALS CORPORATION (JP) 2007-10-25 US disclosed
EP-1753728-A1 PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING SHIKOKU CHEMICALS CORPORATION (JP) 2007-02-21 EP disclosed
EP-1725577-A1 ANTITHROMBOTIC COMPOUND Sanofi-Aventis (FR) 2006-11-29 EP disclosed
WO-2005121101-A1 PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING SHIKOKU CHEMICALS CORPORATION (JP) 2005-12-22 WO disclosed
WO-2005090382-A1 ANTITHROMBOTIC COMPOUND SANOFI-AVENTIS (FR) 2005-09-29 WO disclosed
EP-1574516-A1 Antithrombotic compound Sanofi-Aventis (FR) 2005-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070246134-A1 Phenylnaphthylimidazole Compound and Usage of the Same CYP1A1, CYP1A2, P4HA1 ALDH1A1 27/4885TSHR 1326/4885THRB 2152/4885
US-20070293442-A1 ANTITHROMBOTIC COMPOUND F13B, SERPINC1, SELP ALDH1A1 1008/4885TSHR 1149/4885THRB 1084/4885
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SOD1, SOD3, AOC3 ALDH1A1 482/4885TSHR 2687/4885THRB 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.